Non-invasive Prenatal Testing Market Is Forecast To Reach US$ 3,799.2 million by 2034

Advancements in medical technology have significantly transformed the landscape of prenatal care, offering safer and more accurate options for expectant parents. Non-Invasive Prenatal Testing (NIPT) has emerged as a groundbreaking approach, providing valuable insights into fetal health without the need for invasive procedures. As we look to the future, the Non-Invasive Prenatal Testing market is poised for remarkable growth, driven by technological innovations, increased awareness, and a growing demand for comprehensive prenatal care.

It is projected that the non-invasive prenatal testing (NIPT) market will reach a valuation of US$ 1,447.2 million by 2024. The need for non-invasive prenatal testing is predicted to grow at a 10.1% CAGR worldwide between 2024 and 2034. It is anticipated that the industry will have expanded to a US$ 3,799.2 million valuation by 2034.

Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9632

The non-invasive prenatal testing (NIPT) market is characterized by significant technological breakthroughs, particularly in precision enhancement and the expansion of screening capabilities, exemplified by innovations like next-generation sequencing.

A notable upswing in acceptance rates and market expansion can be attributed to proactive healthcare initiatives and educational programs that contribute to a global understanding of the myriad benefits associated with NIPT.

A noteworthy trend in the industry is the increasing tendency to delay childbirth, a factor that is propelling the demand for non-invasive prenatal testing. As maternal age rises, the importance of NIPT becomes paramount for ensuring precise and timely diagnosis of chromosomal abnormalities, thereby fostering substantial growth in the market. This growing recognition of the indispensable role played by NIPT in addressing genetic concerns aligns with the evolving landscape of prenatal care.

Recent Developments:-

In 2023, Merck, also known as MSD outside of the US and Canada, entered into an agreement with Natera, Inc., a global leader in cell-free DNA testing, wherein Merck would use Natera's real-world database (RWD) to further cancer research.
Natera's oncology RWD includes de-identified clinical and genomic data from more than 100,000 cancer patients in both early and late stages who were tested with SignateraTM, the company's tailored and tumor-informed molecular residual disease (MRD) test.

Key Companies Profiled In This Report

• Genesis Genetics (CopperSurgical Inc.)
• Natera Inc.
• Eurofins LifeCodexx GmbH
• Illumina Inc. (Verinata Health Inc.)
• Centogene N.V.
• MedGenome Labs Ltd.
• Myriad Women's Health Inc. (Counsyl Inc.)
• F. Hoffmann La-Roche Ltd. (Ariosa Diagnostics)
• Qiagen
• Laboratory Corp. of America Holdings
• Progenity Inc.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=9632

Segmentation of Non-Invasive Prenatal Testing Market Research

• Test Type:
o Panel 1 Test
o Panel 2 Test
o Panel 3 Test
• End User:
o Hospitals
o Diagnostic Labs
o Maternity Centres
• Region:
o North America
o Latin America
o Western Europe
o Eastern Europe
o South Asia & Pacific
o East Asia
o Middle East & Africa

Read More: https://www.factmr.com/report/non-invasive-prenatal-testing-market

Contact:
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team : sales@factmr.com

About Fact.MR:
FACT.MR stands out as a premier market research company, acclaimed for its comprehensive market reports and invaluable business insights. With a prominent role in the business intelligence sector, we conducts meticulous analyses, uncovering market trends, growth trajectories, and competitive landscapes across diverse industry sectors. Renowned for its unwavering commitment to accuracy and reliability, FACT.MR empowers businesses with vital data and strategic recommendations, facilitating informed decision-making to improve market positioning. The company's dedication to delivering dependable market intelligence consistently aids enterprises in confidently navigating dynamic market challenges and achieving enduring success.

This release was published on openPR.